Sirius, Cloudflare, Roblox, Medtronic, Qualcomm Trending With Analysts

Analysts are intrested in these 5 stocks: ( (SIRI) ), ( (NET) ), ( (RBLX) ), ( (MDT) ) and ( (QCOM) ). Here is a breakdown of their recent ratings and the rationale behind them.

Sirius XM Holdings is back in the analyst spotlight, but the message is mixed. David Joyce at Seaport Research Partners cut SIRI to Hold, arguing that 2026 guidance, while better than past negative years, still implies slower ARPU growth and higher self‑pay losses as cost savings are plowed back into marketing and product. Yet J.P. Morgan’s Sebastiano Petti moved the stock up to Neutral with a $24 target, citing improving subscriber trends, new offerings like Companion subscriptions, and stabilizing revenue and EBITDA.

Petti now sees 2026 revenue at $8.55 billion and EBITDA at $2.62 billion, both slightly above management’s guidance, helped by stronger Pandora advertising and better churn across all subscriber categories. He expects leverage to drift into the mid‑to‑low‑3x range, opening the door for higher capital returns, while Joyce stays cautious as promotions temper ARPU and self‑pay losses remain elevated. For investors, SIRI is emerging as a slow‑growth, high‑yield media name where expectations have been reset rather than a full‑blown growth story.

Cloudflare is drawing bullish attention as a next‑generation infrastructure and AI platform. Baird’s Shrenik Kothari upgraded NET to Buy with a $260 target, emphasizing its leadership in edge and “agentic AI” workloads and noting that its premium valuation, around 22x forward sales, now looks more reasonable after a pullback. Channel checks point to strong demand for its Workers platform, Zero Trust security, and DDoS services, all supported by flexible pool‑of‑funds contracts that speed deal making and encourage broader use.

After Net’s fourth‑quarter report, Kothari doubled down, upgrading the stock to Outperform as annual contract value jumped roughly 50% year over year and remaining performance obligations climbed 48%. He argues that AI agents, which “never sleep” and hammer hundreds of websites per request, are driving a new wave of high‑density traffic that lifts usage across Cloudflare’s portfolio. With active developers above 4.5 million and some customers shifting all traffic off hyperscalers to Cloudflare, he sees a powerful multi‑year growth runway with consumption and AI monetization as core catalysts.

Roblox is being recast as a growth engine that’s “too good to pass up.” Analyst Eric Handler upgraded RBLX to Buy and raised his price target to $84, pointing to better‑than‑expected 2026 bookings guidance and a projected bookings growth rate above 20% annually. The company just capped 2025 with a huge beat: bookings up 63% and adjusted EBITDA up 83%, driven by 69% daily active user growth and an 88% surge in hours spent on the platform, especially in fast‑growing regions like Asia‑Pacific and Europe.

Handler highlights a virtuous cycle at work: more powerful creation tools are enabling higher‑quality games, which keep users engaged longer and support stronger monetization. He expects 2026 daily active users to reach about 170 million, with only a modest dip in average bookings per user despite mix shifts. Crucially, the 18‑plus audience grew 50% last year and spends roughly 40% more than younger users, while features like SLIM models, server authority, texture streaming, and AI‑driven content tools are designed to keep that higher‑value segment coming back.

Medtronic is drawing fresh optimism as a new product cycle kicks in. Needham’s Michael Matson upgraded MDT to Buy with a $121 target, arguing that the medical device giant is in the early stages of launching several major products in multi‑billion‑dollar markets. He believes these rollouts can add more than one percentage point to Medtronic’s organic revenue growth, a meaningful shift for a company long viewed as a slow‑but‑steady operator.

Matson also sees a governance and strategy angle that could unlock value. Activist investor Elliott Management and new board members are expected to sharpen execution, lift profitability, and accelerate portfolio moves, including the ongoing separation of the Diabetes business and potential M&A. With faster growth and better discipline, he anticipates price‑earnings multiple expansion from current levels, positioning MDT as an appealing pick for investors seeking a blend of defensive healthcare exposure and improving growth.

Qualcomm, by contrast, is starting coverage on a cautious note. Morgan Stanley’s Joseph Moore initiated the stock at Sell with a $132 price target, warning that earnings may have peaked for now as smartphone headwinds intensify. He points to a severe memory shortage that is already prompting some Chinese Android makers to delay shipments, and he expects handset volumes to fall more than management’s current single‑digit decline outlook suggests.

Moore also flags incremental share pressure across Qualcomm’s core mobile franchise. Baseband share at Apple has been slipping for years and is set to fall further, while Samsung is normalizing from last year’s one‑off, 100% share in its flagship phones to a more typical 75%. Within the broader Android market, he sees the potential for further share erosion and growing pushback on royalty payments. Although Qualcomm’s diversification into automotive and data‑center compute is promising, he believes those efforts will take time, leaving the stock in a holding pattern that modestly lags the sector until new engines of growth prove themselves.